NASDAQ:MIRM Mirum Pharmaceuticals Q2 2026 Earnings Report $114.20 +1.17 (+1.04%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$116.54 +2.34 (+2.05%) As of 08:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Mirum Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$0.73Beat/MissN/AOne Year Ago EPSN/AMirum Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$166.03 millionBeat/MissN/AYoY Revenue GrowthN/AMirum Pharmaceuticals Announcement DetailsQuarterQ2 2026Date7/30/2026TimeAfter Market ClosesConference Call DateWednesday, August 5, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Mirum Pharmaceuticals Earnings HeadlinesMirum Pharmaceuticals (MIRM) Projected to Announce Earnings on ThursdayJuly 23, 2026 | americanbankingnews.comMirum Advances New Drug Candidate With Fresh Phase 1 Study UpdateJuly 17, 2026 | tipranks.comThe $8,000 Gold Call Every Retirement Saver Needs to Read Right NowGold didn't creep higher—it broke $5,000, a level many analysts thought would hold. Now JPMorgan, the biggest bank on earth, just raised its 2026 gold forecast to $6,300 and laid out a credible path to $8,000 if everyday investors increase their gold allocations even slightly. Most Americans hold less than 1% in gold, and if that number moves even slightly higher, demand collides with limited supply, and prices reprice fast.July 28 at 1:00 AM | Golden Crest Metals (Ad)Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its PortfolioJuly 4, 2026 | seekingalpha.comThe Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug ZilurgisertibJuly 2, 2026 | finance.yahoo.comIs Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data?June 25, 2026 | insidermonkey.comSee More Mirum Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mirum Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mirum Pharmaceuticals and other key companies, straight to your email. Email Address About Mirum PharmaceuticalsMirum Pharmaceuticals (NASDAQ:MIRM) is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist. Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage. Maralixibat has achieved regulatory approval in the United States for the treatment of cholestatic pruritus in patients with Alagille syndrome and is under review or in clinical development for other rare cholestatic conditions, including progressive familial intrahepatic cholestasis (PFIC). In addition to its lead compound, Mirum maintains a pipeline of product candidates aimed at expanding the therapeutic options available to patients with orphan liver diseases. Founded in 2016 and headquartered in Brisbane, California, Mirum Pharmaceuticals operates with a patient-centric approach that emphasizes collaboration with advocacy groups and key opinion leaders in hepatology. Under the leadership of President and Chief Executive Officer Derek Chalmers, the company is actively pursuing regulatory approvals and commercial partnerships to bring its therapies to patients in the United States and international markets.View Mirum Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AMD’s AI Bubble Could Burst Into Explosive UpsideRefiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?Atlassian’s AI Pivot Is Starting to Challenge Wall Street’s Bear CaseVerizon May Be an AI Infrastructure Stock Hiding in Plain SightApple’s Earnings Setup Puts Its Record Rally and AI Patience to the TestWintrust: A Quiet Regional Bank Posting Loud ResultsMarketBeat Week in Review – 07/20- 07/24 Upcoming Earnings Agnico Eagle Mines (7/29/2026)General Dynamics (7/29/2026)L3Harris Technologies (7/29/2026)Automatic Data Processing (7/29/2026)Amphenol (7/29/2026)ARM (7/29/2026)Fortinet (7/29/2026)Lam Research (7/29/2026)Meta Platforms (7/29/2026)Microsoft (7/29/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
